Abstract
Elactocin is a novel anti-tumour antibiotic which has potent activity in vitro against a range of tumours. This phase I trial of elactocin identified the dose-limiting toxicity as profound anorexia and malaise. The schedules used included 1 h infusion 3 weekly, 24 h infusion 3 weekly, 1 h infusion daily x 5 (3 weekly), 1 h infusion weekly and finally continuous 5 day intravenous infusion. On all these schedules dose-limiting toxicity was the same and as no partial or complete responses were identified, we do not recommend that further trials of elactocin are performed.
Full text
PDF![648](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b15/2074658/804a5dc0239b/brjcancer00020-0158.png)
![649](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b15/2074658/03d4dbe0f7f5/brjcancer00020-0159.png)
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Leopold W. R., Shillis J. L., Mertus A. E., Nelson J. M., Roberts B. J., Jackson R. C. Anticancer activity of the structurally novel antibiotic Cl-920 and its analogues. Cancer Res. 1984 May;44(5):1928–1932. [PubMed] [Google Scholar]
- Roberts B. J., Hamelehle K. L., Sebolt J. S., Leopold W. R. In vivo and in vitro anticancer activity of the structurally novel and highly potent antibiotic CI-940 and its hydroxy analog (PD 114,721). Cancer Chemother Pharmacol. 1986;16(2):95–101. doi: 10.1007/BF00256156. [DOI] [PubMed] [Google Scholar]
- Tunac J. B., Graham B. D., Dobson W. E., Lenzini M. D. Novel antitumor antibiotics, CI-940 (PD 114,720) and PD 114,721. Taxonomy, fermentation and biological activity. J Antibiot (Tokyo) 1985 Apr;38(4):460–465. doi: 10.7164/antibiotics.38.460. [DOI] [PubMed] [Google Scholar]